Eli Lilly's new diabetes drug continues to show promise as an obesity treatment

Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.

from Health and Science https://ift.tt/s0zvAbc
https://ift.tt/26yscLK
https://ift.tt/VmqXjb4